1 of the Biggest Risks Facing Novavax Has Now Been Resolved: Is Now the Time to Buy the Stock?
Since 2021, shares of (NASDAQ: NVAX) have absolutely crumbled, falling by a whopping 95%. Even with the price rally in recent days, the stock has still been a disastrous investment over the past few years. The price drop was justified largely because the company's fate was uncertain. There were question marks relating to its growth and a canceled purchase agreement.
The good news is that one of those issues recently reached a positive resolution. Is that enough to make this beaten-down stock worth taking a chance on?
One of the clouds hanging over Novavax was a dispute with a global vaccine organization called Gavi, the Vaccine Alliance. The issue goes back to 2022 when Novavax terminated a purchase agreement with Gavi after it didn't procure the doses it had previously agreed to buy. Gavi paid $700 million in advance, which it ended up wanting a refund for as the shots weren't needed anymore. But Novavax said the payments were nonrefundable.
Source Fool.com
Novavax Inc. Aktie
Die Community bevorzugt leicht Novavax Inc. mit mehr Buy- als Sell-Einschätzungen.
Mit einem Kursziel von 22 € für Novavax Inc., würde dies eine mehr als zweifache Steigerung des aktuellen Kurses von 9.9 € bedeuten.
